Abstract:We performed a comprehensive study to assess the pathogenicity of a novel transient receptor potential melastatin 4 (TRPM4) mutation and to pinpoint underlying molecular mechanisms using an induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) model. Patient-specific iPSC-CMs exhibited arrhythmic phenotype manifesting delayed afterdepolarizations (DADs) and paroxysmal cellular flutter (PCF), which were rescued by correction of the causal mutation. T262M conferred impaired TRPM4 channel function by enhanced ubiquitination for protein degradation via the lysosomal pathway, resulting in abnormal Ca2+ cycling and elevated diastolic intracellular Ca2+ ([Ca2+]i). Mechanistically, hyperactivation of platelet-derived growth factor receptor β (PDGFRB) signalling derived arrhythmic events in diseased iPSC-CMs. On the contrary, pharmacological and genetic inhibition of PDGFRB effectively restored diastolic [Ca2+]i and rescued the arrhythmic phenotype in T262M myocytes. Brugada syndrome (BrS) is an inherited arrhythmogenic disease featured by a high risk of sudden cardiac death.1 TRPM4 mutations have been reported to be associated with BrS,2-4 whereas the underlying mechanisms remain unknown. In this study, we recruited a 21-year-old male patient who is asymptomatic and no abnormality was found by echocardiography. However, his electrocardiogram showed a characteristic type 2 BrS pattern, with ST-segment morphology representing saddleback-type elevation in lead V2 (Figure S1A). In addition, we further monitored the electrocardiogram in lead V1 and V2 from one or two intercostal spaces higher than the standard position (Figure S1B). The genetic screening revealed a single missense mutation (c.785C > T, p.T262M) in TRPM4 (Figure S1C–E). The mutation, located at the N terminus of the TRPM4 channel, is highly conserved among spices and is graded as a variant of uncertain significance (Figure S1F,G). Our healthy control subject was a 21-year-old female. Skin fibroblasts were reprogrammed using nonintegrated Sendai virus and iPSCs were successfully generated and characterized (Figures S1H–L, S2 and S3). Genetic sequencing confirmed that T262M mutation was present in patient iPSCs but not in controls (Figure S1M). The iPSC-CMs were subsequently generated by a small molecule-based monolayer differentiation protocol (Figures S4 and S5). Single-cell patch clamp recordings revealed a uniform and rhythmic action potential (AP) profile in control iPSC-CMs (Figure 1A). However, arrhythmic waveforms were seen in a large proportion of patient iPSC-CMs, manifesting two distinct phenotypes: the more common phenotype was DAD; the other rare but more severe phenotype was PCF (Figure 1B,C,G). Moreover, we observed significantly increased peak interval variability and shortened AP duration (APD) in patient iPSC-CMs (Figure 1H,I and Table S1). We next generated isogenic control lines by CRISPR/Cas9-mediated genome editing technology (Figure S2 and S6). The gene-corrected (GC) iPSC-CMs showed a dramatic reduction of arrhythmic incidence and resembled the AP profile of controls (Figure 1D,G–I, Figures S4, S5 and Table S1). TRPM4 knockout (KO) iPSC lines were also generated by CRISPR/Cas9 (Figures S2, S7 and S8). KO iPSC-CMs recapitulated abnormal AP phenotype of patient iPSC-CMs (Figure 1E–I, Figures S4, S5 and Table S1). Taken together, these results demonstrate that TRPM4 T262M is a pathologic mutation that causes the arrhythmic phenotype. To assess if T262M gave rise to TRPM4 channel dysfunction, we next performed patch clamp on human embryonic kidney 293T cells transiently expressing TRPM4 (Figure 2A). The current density was significantly reduced in T262M channels as compared to wildtype (WT) (Figure 2B,C). Through molecular modelling, we observed no significant change of TRPM4 channel structure affected by T262M (Figure S9). Biotinylation assay revealed that total and surface expression levels of TRPM4 protein were significantly decreased in T262M channels, whereas the ratio of surface-to-total expression levels remained unchanged (Figure 2D–G). Consistently, the endogenous TRPM4 protein expression was markedly decreased in patient iPSC-CMs (Figure 2H,I). Given that the TRPM4 channel is activated by [Ca2+]i,5 we sought to investigate if T262M affected TRPM4 channel activation upon [Ca2+]i stimulation. Patch clamp recordings were performed in inside-out mode, allowing the cytosolic side of the patch perfused by escalated [Ca2+]i. We observed significantly reduced [Ca2+]i-activated TRPM4 current density and right-shifted current-[Ca2+]i curve in T262M channels, suggesting a weakened sensitivity to [Ca2+]i (Figure 2J–M). Moreover, we observed a markedly elevated level of ubiquitinated TRPM4 protein in T262M channels using the ubiquitin antibody P4D1 (Figure S10A,B). Inhibition of lysosome pathway by chloroquine effectively rescued T262M-induced down-regulation of TRPM4 protein and reduction of TRPM4 currents (Figure S10C–I). Collectively, these results indicate that T262M confers impaired TRPM4 channel function by enhanced ubiquitination for protein degradation via the lysosomal pathway. Alterations in Ca2+ cycling are a common trigger of cardiac arrhythmias.6 More attention has been attracted to the roles of Ca2+ signalling in arrhythmogenic mechanisms of BrS.7 To test whether T262M affects Ca2+ homeostasis, Ca2+ imaging was performed using fura-2 AM dye to ratiometrically record Ca2+ transients in iPSC-CMs (Figure S11A–C). Patient iPSC-CMs exhibited “arrhythmia-like” irregular transients, dysregulation of Ca2+ cycling and elevation of diastolic [Ca2+]i (Figure S11D–L and Table S2). Interestingly, L-type Ca2+ current density was markedly increased in T262M iPSC-CMs, and treatment of verapamil in T262M iPSC-CMs drastically ameliorated the incidence of irregular transients (Figure S11M–T). These results demonstrate that disrupted Ca2+ homeostasis is associated with arrhythmic phenotype caused by T262M. To understand the molecular mechanisms of how TRPM4 T262M causes arrhythmic phenotype, we performed genome-wide RNA sequencing by comparing control, KO, patient and GC iPSC-CMs (Figure 3A–C). Gene ontology analysis revealed that differentially expressed genes were enriched in ion channel-, Ca2+ signalling-, cardiac action potential and conduction, and PDGF signalling-related terms (Figure 3D). Interestingly, we found greatly enhanced PDGFRB expression in KO or patient iPSC-CMs (Figure 3D–H). Previous studies have reported that PDGFRB signalling regulates cardiomyocyte proliferation and myocardial regeneration, and over-activation of PDGFRB signalling is closely associated with atrial fibrillation and dilated cardiomyopathy.8-10 Notably, treatment of PDGFRB inhibitors or knockdown of PDGFRB expression in patient iPSC-CMs largely reduced PDGFRB protein expression, greatly attenuated proarrhythmic activities, and restored elevated diastolic [Ca2+]i (Figure 4). Altogether, these results suggest that hyperactivation of PDGFRB signalling contributes to arrhythmogenesis in TRPM4-related BrS. In conclusion, genome editing of iPSC-CMs can offer a precision medicine approach for identifying pathogenic mutation of BrS in a dish. More importantly, our findings reveal novel molecular mechanisms and potential therapeutic targets of TRPM4-related BrS (Figure S12). We would like to thank the core facility of Zhejiang University Institute of Translational Medicine for assistance with flow cytometry and confocal microscopy experiments. This work was supported by National Key R&D Program of China (No. 2017YFA0103700) (P.L.), National Natural Science Foundation of China (No. 81922006, 81870175, 31571528) (P.L.), and Natural Science Foundation of Zhejiang Province (No. LD21H020001, LR15H020001) (P.L.). P.L. would like to thank Natalie Liang and Michael Liang for their encouragement and consistent support. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:In the present study, we show that the Calcium Voltage-Gated Channel Auxiliary Subunit Beta 2 (CACNB2) variant c.1439C>T/p.S480L is linked to the clinical phenotype of short QT syndrome 5 (SQTS5) overlapped with Brugada syndrome (BrS). The PI3K pathway may contribute to the arrhythmogenesis of the disease. PI3K-activator and amiodarone but not sotalol may be effective drugs for treating arrhythmias in SQTS5-patients carrying but not limited to this variant. The SQTS is characterized by a shortening of the corrected QT (QTc) interval, which has been linked to sudden cardiac death.1, 2 Implantable cardioverter-defibrillator therapy is associated with numerous complications.3 Therefore, drug therapy is important to optimize the treatment of SQTS patients. Recently published data have reported that hydroquinidine is effective in prolonging the QTc interval in SQTS patients. Notably, data have shown that hydroquinidine might exert different effects depending on the genetic variant and/or SQTS form.4, 5 Based on the limited evidence of the clear role of variants in calcium channel subunits in SQTS and the absence of alternative therapies in this rare cohort,6 we aimed to use cardiomyocytes from induced pluripotent stem cells (hiPSC-CMs) derived from a SQTS5-patient overlapped with BrS carrying a variant in CACNB2 to study the significance of the variant for the clinical phenotype by combining gene editing and electrophysiological analysis in order to identify possible effective drugs for the disease. HiPSC-CMs offered advantages over other models to model channelopathies in the dish.7, 8 For this study, human iPSC lines from one SQTS patient, from two healthy donors, and two Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-edited hiPSC lines were used (Figure S1A,B). The hiPSC lines were verified for pluripotency (Figure S1C–E) and were differentiated into cardiomyocytes (Figure S1F), showing cardiac action potential (AP) features (Figure S2). The SQTS patient showed an abbreviated QTc interval with a QTc of 330 ms (Figure 1A) and was admitted due to an aborted cardiac arrest. A genetic screening of SQTS related genes of this patient detected a variant, namely c.1439C>T/p.S480L (dbSNP rs121917812; Clinvar RCV000010155.3; NM_000724.4: c.1439C>T; NM_201590.3: c.1442C>T) in CACNB2, a beta-subunit of L-type calcium channel (Figure 1C). Sequencing of SQTS related genes confirmed the existence of the same variant in other first or second-degree relatives (Figure 1B,C) with a SQTS and BrS phenotype. The durations of AP at 50% (APD50) and 90% repolarization (APD90) were significantly shorter in SQTS5 cells compared to that in the cells from the healthy donor and isogenic control cells (Figure 1D–F). The maximal depolarization speed (Vmax) of APs was decreased (Figure 1G). Of note, the APD-shortening remained at all the tested frequencies. In addition, HD-MEA recordings detected that the field potential duration in SQTS5-hiPSC-CMs was also significantly shorter compared to the healthy or isogenic control (Figure 1H–I). In recordings of spontaneous APs, the frequency of cell beating in SQTS5-hiPSC-CMs was significantly slower than that in healthy cells, without difference in maximal diastolic potential (Figure S3C,D,G,H). After the APD parameters were corrected for beating frequency (Bazett´s correction), the corrected APDs were also shorter in SQTS5-hiPSC-CMs (Figure S3C–F). The L-type calcium channel current (ICa-L) was significantly decreased in SQTS5-hiPSC-CMs as compared to that from the healthy control and isogenic control (Figure 2A,B). The activation curve of ICa-L in SQTS5-cells was shifted to more positive potentials compared with that in isogenic control hiPSC-CMs. Besides, the inactivation curve shifted to more negative potentials, and recovery from inactivation decelerated in SQTS5-hiPSC-CMs compared with both healthy and isogenic control cells (Figure 2C–H). Western blot and immunostaining analyses detected that the protein expression level of CACNB2 was significantly decreased in SQTS5-hiPSC-CMs (Figure S4). The alpha subunit of L-type Ca2+ channel CACNA1C was slightly increased in cell lysates (Figure S4) but not in the cell membrane (Figure S4). Since loss-of-function of the sodium channel is a main feature of BrS, the peak sodium channel current (INa) and their kinetics were assessed (Figure 3A,B and Figure S5A–F). In SQTS5-hiPSC-CMs, the peak INa and activation were significantly suppressed compared to healthy cells. To test the arrhythmogenicity of hiPSC-CMs of the SQTS5-patient, spontaneous calcium transients and spontaneous APs were recorded. Compared to healthy donor and isogenic control cells, a higher number of SQTS5-cells displayed arrhythmic events (irregular or triggered beats) (Figure 3C–F). The interval variability (standard deviation of beating intervals) in SQTS5-hiPSC-CMs was larger than that in donor and isogenic control cells (Figure 3C–F). For details about methods, please see Supporting Information. As expected, insertion of the present CACNB2 variant using CRISPR/Cas 9 in a further control cell line (Figure S6) led to a loss-of-function of ICa-L and an APD-shortening with a reduction of Vmax (Figure S7). Quinidine and amiodarone prolonged APD (Figures S8 and S9) but only amiodarone showed a significant antiarrhythmic effect (Figure S9). Sotalol showed no effect in SQTS5-cells although it prolonged APD in healthy cells (Figures S10 and S11). Since the PI3K pathway may influence ion channel function and QT interval,9, 10 we measured the protein levels of PI3K and Akt. Both total and phosphorylation levels of Akt and PI3K were decreased in SQTS5-hiPSC-CMs compared to healthy cardiomyocytes (Figure 4A–C). Whereas a PI3K-activator (IGF-1, 100 ng/ml) reduced the interval variability and arrhythmic events, a PI3K blocker (alpelisib, 5 μM) enhanced both (Figure 4D–F). In addition, the PI3K-activator prolonged the APD (Figure 4G,H). In conclusion, the variant c.1439C>T/p.S480L in the CACNB2 gene is responsible for phenotypic changes of SQTS5 overlapping with BrS. Amiodarone reduces arrhythmic events in the dish and based on this, we may assume that it may be clinically more effective than quinidine for treating SQTS5 and /or BrS. The PI3K/Akt activity can be reduced in SQTS5 and an activator of this signaling pathway may rescue the phenotype. This study was supported by the Hector-Stiftung and DZHK (German Center for Cardiovascular Research. Furthermore this study is supported by NSFC 81870261, Sichuan Youth Science and Technology Innovation Research Team 2020JDTD0024, Collaborative Innovation Center for the Prevention and Treatment of Cardiovascular Diseases in Sichuan Province xtcx2016-14 and interrnational cooperation project of Science & Technology Department of Sichuan Province (No. 2020YFH0139) Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Novel Insights in the Pathomechanism of Brugada Syndrome and Fever‐related Type 1 ECG Changes in a Preclinical Study Using Human‐induced Pluripotent Stem Cell‐derived Cardiomyocytes

Patient-Specific and Genome-Edited Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Brugada Syndrome

Patient-specific Ipsc-Derived Cardiomyocytes Reveal Aberrant Activation of Wnt/β-catenin Signaling in SCN5A-related Brugada Syndrome

Cellular Modeling and Simulation of Brugada Syndrome

Studying Brugada Syndrome with an SCN1B Variants in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Hyperactivation of platelet‐derived growth factor signalling contributes to arrhythmogenesis in Brugada syndrome

Generation of an Induced Pluripotent Stem Cell Line from a Brugada Syndrome Patient Carrying SCN5A/c.3118G>C Mutation

A Cellular Model of Brugada Syndrome with SCN10A Variants Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Transcriptional Dysregulation Underlies Both Monogenic Arrhythmia Syndrome and Common Modifiers of Cardiac Repolarization

Patient-specific Ipsc-Derived Cardiomyocytes Reveal Variable Phenotypic Severity of Brugada Syndrome.

Deciphering the Pathogenic Role of a Variant with Uncertain Significance for Short QT and Brugada Syndromes Using Gene‐edited Human‐induced Pluripotent Stem Cell‐derived Cardiomyocytes and Preclinical Drug Screening

A mutation causing Brugada syndrome identifies a mechanism for altered autonomic and oxidant regulation of cardiac sodium currents

The relationship between Brugada-like electrocardiographic pattern unmasked by fever and SCN5A gene variations

Simulation of Brugada Syndrome Using Cellular and Three-Dimensional Whole-Heart Modeling Approaches

Electrophysiological Characteristics Of A Scn5a Voltage Sensors Mutation R1629q Associated With Brugada Syndrome

Brugada Syndrome: A Comprehensive Review of Pathophysiological Mechanisms and Risk Stratification Strategies.

Brugada Syndrome Manifesting Only During Fever in Patient with Septic Shock Secondary to Post-Obstructive Pneumonia

Gain‐of‐Function KCNH2 Mutations in Patients with Brugada Syndrome

Why Is Only Type 1 Electrocardiogram Diagnostic of Brugada Syndrome? Mechanistic Insights From Computer Modeling

Phase 2 Re-Entry Without Ito: Role of Sodium Channel Kinetics in Brugada Syndrome Arrhythmias.

Molecular genetics of Brugada syndrome